Top 5 Stocks to Buy Now
→ Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla) (From Brownstone Research) (Ad)tc pixel Free LXRX Stock Alerts

Lexicon Pharmaceuticals (LXRX) Short Interest Ratio & Short Volume

Lexicon Pharmaceuticals logo
$2.16 +0.01 (+0.47%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$2.15 -0.01 (-0.23%)
As of 06/23/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Lexicon Pharmaceuticals Short Interest Overview

As of May 29, 2026, Lexicon Pharmaceuticals (LXRX) had a short interest of 26.21 million shares sold short, representing 6.86% of the public float. This marks a 0.25% increase in short interest since the prior report. The short interest ratio (days to cover) is 13.7, meaning it would take 13.7 days of the average trading volume of 2.11 million shares to cover all short positions.

Current Short Interest
26,206,147 shares
Previous Short Interest
26,140,915 shares
Change Vs. Previous Month
0.25%
Dollar Volume Sold Short
$57.13 million
Short Interest Ratio
13.7 Days to Cover
Last Record Date
May 29, 2026
Outstanding Shares
444,200,000 shares
Short Percent of Float
6.86%
Today's Trading Volume
2,773,640 shares
Average Trading Volume
2,112,443 shares
Today's Volume Vs. Average
131%
Short Selling Lexicon Pharmaceuticals?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

LXRX Short Interest Over Time

LXRX Days to Cover Over Time

LXRX Percentage of Float Shorted Over Time

Lexicon Pharmaceuticals Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/29/202626,206,147 shares $57.13 million +0.3%6.9%13.74 $2.18
5/15/202626,140,915 shares $58.29 million +9.6%6.8%6.22 $2.23
4/30/202623,857,393 shares $38.41 million +0.8%6.2%13.59 $1.61
4/15/202623,674,019 shares $44.03 million +3.2%6.2%11.62 $1.86
3/31/202622,932,295 shares $35.77 million +1.1%6.3%9.07 $1.56
3/13/202622,693,812 shares $38.35 million -1.9%6.2%7.14 $1.69
2/27/202623,139,559 shares $34.02 million -5.6%6.3%12.65 $1.47
2/13/202624,523,367 shares $32.13 million -0.3%6.4%8.57 $1.31
1/30/202624,583,755 shares $28.52 million -2.3%7.9%4.69 $1.16
1/15/202625,160,782 shares $32.21 million +6.3%8.0%17.95 $1.28
12/31/202523,660,410 shares $27.21 million +1.4%7.6%12.34 $1.15
12/15/202523,344,944 shares $28.71 million -3.6%7.5%16.82 $1.23
11/28/202524,226,907 shares $34.16 million -1.7%7.7%16.97 $1.41
11/14/202524,649,659 shares $36.73 million -11.0%7.9%8.42 $1.49
10/31/202527,704,594 shares $38.23 million +3.2%8.9%16.5 $1.38
10/15/202526,830,000 shares $41.05 million -1.7%8.6%11.2 $1.53
9/30/202527,300,000 shares $36.86 million -3.8%N/A10.1 $1.35
9/15/202528,380,000 shares $31.79 million -1.6%N/A8.8 $1.12
8/31/202528,840,000 shares $31.72 million +3.3%9.2%8.6 $1.10
8/15/202527,910,000 shares $34.61 million +3.1%N/A7.6 $1.24
7/31/202527,060,000 shares $28.95 million -7.4%8.6%6.6 $1.07
7/15/202529,210,000 shares $33.59 million -12.0%N/A6.2 $1.15
6/30/202533,210,000 shares $31.41 million -11.6%10.7%6.1 $0.95
6/15/202537,560,000 shares $25.22 million -3.3%12.1%2.8 $0.67
5/31/202538,830,000 shares $24.94 million -9.8%16.9%2.9 $0.64
5/15/202543,030,000 shares $22.81 million +15.5%18.8%2.9 $0.53
4/30/202537,270,000 shares $27.24 million -9.8%N/A2.5 $0.73
4/15/202541,330,000 shares $21.17 million -5.8%18.0%2.8 $0.51
3/31/202543,880,000 shares $20.22 million +11.8%19.1%3 $0.46
3/15/202539,260,000 shares $14.39 million -17.3%17.1%6.3 $0.37
2/28/202547,460,000 shares $33.51 million +6.1%20.7%7.3 $0.71
2/15/202544,740,000 shares $35.12 million +4.0%19.5%9.3 $0.78
1/31/202543,030,000 shares $32.54 million +10.1%N/A9 $0.76
1/15/202539,100,000 shares $28.45 million +16.7%N/A8 $0.73
12/31/202433,500,000 shares $24.74 million +7.1%N/A7.8 $0.74
12/15/202431,280,000 shares $25.35 million -0.8%N/A7.6 $0.81
11/30/202431,530,000 shares $25.22 million +0.5%N/A9.6 $0.80
11/15/202431,380,000 shares $30.60 million +9.5%N/A9.7 $0.98
10/31/202428,650,000 shares $55.87 million +3.6%N/A9.5 $1.95
10/15/202427,650,000 shares $49.49 million +2.5%N/A10.1 $1.79
A letter from Shannon Stansberry (Ad)

Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel

Watch the full story and see the verified track record for yourself
9/30/202426,970,000 shares $42.34 million +1.3%N/A9.4 $1.57
9/15/202426,630,000 shares $45.27 million +4.9%N/A9.5 $1.70
8/31/202425,390,000 shares $43.92 million +3.5%N/A8.8 $1.73
8/15/202424,530,000 shares $40.23 million +9.8%N/A8.5 $1.64
7/31/202422,350,000 shares $50.29 million +7.0%N/A8 $2.25
7/15/202420,880,000 shares $44.27 million +3.4%N/A7.6 $2.12
6/30/202420,200,000 shares $33.94 million -6.4%N/A7.8 $1.68
6/15/202421,570,000 shares $39.26 million -14.2%N/A7.7 $1.82
5/31/202425,140,000 shares $42.74 million +8.0%N/A7.3 $1.70
5/15/202423,270,000 shares $45.14 million -0.7%N/A6.3 $1.94
4/30/202423,440,000 shares $36.10 million +16.5%N/A5.3 $1.54
4/15/202420,120,000 shares $37.62 million -8.2%N/A4.2 $1.87
3/31/202421,910,000 shares $52.58 million +2.6%N/A4.7 $2.40
3/15/202421,350,000 shares $55.51 million +1.3%N/A4.6 $2.60
2/29/202421,070,000 shares $52.46 million -10.0%N/A4.9 $2.49
2/15/202423,410,000 shares $83.81 million +1.7%N/A6.4 $3.58
1/31/202423,030,000 shares $43.07 million -8.9%N/A8 $1.87
1/15/202425,270,000 shares $34.62 million +8.8%N/A10.3 $1.37
12/31/202323,220,000 shares $35.53 million -0.3%N/A8.6 $1.53
12/15/202323,280,000 shares $29.57 million -0.5%N/A9.1 $1.27
11/30/202323,400,000 shares $24.80 million +4.6%N/A9.3 $1.06
11/15/202322,370,000 shares $25.50 million +1.8%N/A9.3 $1.14
10/31/202321,980,000 shares $27.26 million +12.7%N/A9.9 $1.24
10/15/202319,500,000 shares $23.21 million -3.7%N/A9.1 $1.19
9/30/202320,240,000 shares $22.06 million +7.1%N/A11.2 $1.09
9/15/202318,900,000 shares $26.46 million +6.1%N/A11.5 $1.40
8/31/202317,810,000 shares $30.63 million +1.5%N/A9.5 $1.72
8/15/202317,550,000 shares $28.61 million -2.2%N/A6.6 $1.63
7/31/202317,950,000 shares $36.08 million +14.2%N/A6.9 $2.01
7/15/202315,720,000 shares $34.74 million +8.7%N/A6.3 $2.21
6/30/202314,460,000 shares $33.11 million +38.0%N/A6.1 $2.29
6/15/202310,480,000 shares $26.93 million -2.6%N/A4.9 $2.57
5/31/202310,760,000 shares $35.51 million +66.8%N/A6.3 $3.30
5/15/20236,450,000 shares $19.22 million +30.8%N/A8.5 $2.98
4/30/20234,930,000 shares $11.78 million +17.4%N/A8.1 $2.39
4/15/20234,200,000 shares $10.12 million +3.5%N/A9.5 $2.41
3/31/20234,060,000 shares $9.87 million +2.3%N/A10.3 $2.43
3/15/20233,970,000 shares $9.09 million +4.2%N/A9.3 $2.29
2/28/20233,810,000 shares $8.57 million -8.0%N/A9.3 $2.25
2/15/20234,140,000 shares $9.44 million +3.5%N/A11.3 $2.28
1/31/20234,000,000 shares $8.96 million +2.6%N/A10.6 $2.24
1/15/20233,900,000 shares $9.20 million +0.3%N/A9.8 $2.36
12/30/20223,890,000 shares $7.43 million +2.9%N/A9.3 $1.91
12/15/20223,780,000 shares $8.05 million +0.3%N/A8.6 $2.13
11/30/20223,770,000 shares $8.07 million -2.3%N/A7.8 $2.14
11/15/20223,860,000 shares $8.96 million -9.4%N/A7.5 $2.32
10/31/20224,260,000 shares $9.16 million -4.7%N/A6.4 $2.15
10/15/20224,470,000 shares $9.43 million -0.2%N/A4.4 $2.11
9/30/20224,480,000 shares $10.75 million +11.4%N/A4.3 $2.40
9/15/20224,020,000 shares $10.77 million +7.8%N/A2.4 $2.68
My feud with Zohran Mamdani (Ad)

Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson says what's unfolding in New York City is just the beginning. Tilson, a Harvard MBA who spent 30 years on Wall Street, has identified a specific economic pattern he believes points to a financial reset unlike anything seen in over 100 years. He's released a free analysis outlining what's coming and the exact steps he recommends you take with your money now.tc pixel

Read Whitney Tilson's free analysis and protect your wealth today
8/31/20223,730,000 shares $10.26 million +1.9%N/A2.2 $2.75
8/15/20223,660,000 shares $12.55 million -55.2%N/A2.2 $3.43
7/31/20228,170,000 shares $19.44 million -0.9%N/A5.3 $2.38
7/15/20228,240,000 shares $25.38 million +6.6%8.0%6.9 $3.08
6/30/20227,730,000 shares $14.38 million +34.4%7.5%6.6 $1.86
6/15/20225,750,000 shares $8.05 million +5.7%5.6%10.5 $1.40
5/31/20225,440,000 shares $9.63 million +1.3%N/A10.9 $1.77
5/15/20225,370,000 shares $9.29 million +0.9%N/A8.8 $1.73
4/30/20225,320,000 shares $9.63 million +11.5%N/A8.4 $1.81
4/15/20224,770,000 shares $11.11 million +2.8%N/A7.3 $2.33
3/31/20224,640,000 shares $9.70 million -2.1%N/A7.1 $2.09
3/15/20224,740,000 shares $9.24 million -2.1%N/A6.8 $1.95
2/28/20224,840,000 shares $10.02 million +8.3%N/A6.8 $2.07
2/15/20224,470,000 shares $13.50 million +17.6%N/A7 $3.02
1/31/20223,800,000 shares $12.05 million +5.3%N/A5.9 $3.17
1/15/20223,610,000 shares $12.45 million +1.4%N/A5.6 $3.45
12/31/20213,560,000 shares $14.03 million +10.9%N/A5 $3.94
12/15/20213,210,000 shares $12.78 million -10.6%N/A4.3 $3.98
11/30/20213,590,000 shares $16.44 million -0.6%N/A4.9 $4.58
11/15/20213,610,000 shares $18.59 million +8.4%N/A4.1 $5.15
10/29/20213,330,000 shares $17.62 million -2.4%2.4%3.5 $5.29
10/15/20213,410,000 shares $21.01 million -2.9%2.4%3.6 $6.16
9/30/20213,510,000 shares $16.88 million -4.6%2.5%3.8 $4.81
9/15/20213,680,000 shares $16.71 million -11.1%2.6%3.4 $4.54
8/31/20214,140,000 shares $19.54 million +16.6%3.0%4 $4.72
8/13/20213,550,000 shares $12.89 million -8.5%2.5%4 $3.63
7/30/20213,880,000 shares $13.74 million -3.2%2.8%4.7 $3.54
7/15/20214,010,000 shares $14.80 million -8.2%2.9%4.9 $3.69
6/30/20214,370,000 shares $20.06 million +24.2%3.1%5.2 $4.59

LXRX Short Interest - Frequently Asked Questions

Short interest is the volume of Lexicon Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 29th, traders have sold 26,206,147 shares of LXRX short. 6.86% of Lexicon Pharmaceuticals' shares are currently sold short. Learn More on Lexicon Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LXRX shares currently have a short interest ratio of 13.7. Learn More on Lexicon Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.86% of Lexicon Pharmaceuticals' floating shares are currently sold short.

Lexicon Pharmaceuticals saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 26,206,147 shares, an increase of 0.2% from the previous total of 26,140,915 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

6.86% of Lexicon Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Lexicon Pharmaceuticals: Celldex Therapeutics, Inc. (9.60%), BioCryst Pharmaceuticals, Inc. (14.99%), Innoviva, Inc. (8.10%), Novavax, Inc. (28.41%), Zenas BioPharma, Inc. (22.09%), MannKind Corporation (10.08%), OPKO Health, Inc. (8.70%), Geron Corporation (11.38%), Rigel Pharmaceuticals, Inc. (23.75%), Ironwood Pharmaceuticals, Inc. (10.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($81.27 billion), Invesco QQQ ($49.06 billion), iShares Russell 2000 ETF ($23.61 billion), Western Digital Corporation ($16.93 billion), Sandisk Corporation ($15.61 billion), Salesforce Inc. ($11.65 billion), SPDR S&P Biotech ETF ($10.52 billion), Nebius Group N.V. ($10.24 billion), Lumentum Holdings Inc. ($8.74 billion), and iShares iBoxx $ High Yield Corporate Bond ETF ($8.21 billion). View all of the most shorted stocks.

Short selling LXRX is an investing strategy that aims to generate trading profit from Lexicon Pharmaceuticals as its price is falling. LXRX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lexicon Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LXRX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LXRX, twice per month. The most recent reporting period available is May, 29 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like LXRX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:LXRX) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Top Banks Warn: A Strange Day is Coming to America
Goldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...
TradeSmith | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
Read this before you touch SPCX
SPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...
Altimetry | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
Karp just filed Form 144
On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...
Porter & Company | Sponsoredtc pixel